Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

por Egami, Saeka, Kawazoe, Hitoshi, Hashimoto, Hironobu, Uozumi, Ryuji, Arami, Toko, Sakiyama, Naomi, Ohe, Yuichiro, Nakada, Hideo, Aomori, Tohru, Ikemura, Shinnosuke, Fukunaga, Koichi, Yamaguchi, Masakazu, Nakamura, Tomonori
Publicado 2021

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study

por Egami, Saeka, Kawazoe, Hitoshi, Hashimoto, Hironobu, Uozumi, Ryuji, Arami, Toko, Sakiyama, Naomi, Ohe, Yuichiro, Nakada, Hideo, Aomori, Tohru, Ikemura, Shinnosuke, Fukunaga, Koichi, Yamaguchi, Masakazu, Nakamura, Tomonori
Publicado 2021

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cance...

por Ogiwara, Toshiki, Kawazoe, Hitoshi, Egami, Saeka, Hashimoto, Hironobu, Saito, Yoshimasa, Sakiyama, Naomi, Ohe, Yuichiro, Yamaguchi, Masakazu, Furukawa, Tetsuya, Hara, Azusa, Hiraga, Yui, Jibiki, Aya, Yokoyama, Yuta, Suzuki, Sayo, Nakamura, Tomonori
Publicado 2021

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight

por Fujiwara, Yutaka, Makihara, Reiko, Hase, Tetsunari, Hashimoto, Naozumi, Naito, Tomoyuki, Tsubata, Yukari, Okuno, Takae, Takahashi, Toshiaki, Kobayashi, Haruki, Shinno, Yuki, Zenke, Yoshitaka, Ikeda, Takaya, Hosomi, Yukio, Watanabe, Kageaki, Kitazono, Satoru, Sakiyama, Naomi, Makino, Yoshinori, Yamamoto, Noboru
Publicado 2023